|For Immediate Release
Vantage Oncology Teams with Metro Chicago Surgical Oncology to Open New MCSO Radiation Oncology Center - Advanced Radiation Oncology Services to be Spearheaded by Timothy Hollister, M.D.
Manhattan Beach, CA (January 25, 2013) – In its continued efforts to bring advanced radiation oncology services to cancer patients in the Chicago North Shore area, Vantage Oncology, a Manhattan Beach, CA-based developer and operator of radiation oncology facilities, has teamed with Metro Chicago Surgical Oncology (MCSO) and they are pleased to announce the opening of MCSO Radiation Oncology Center in Wilmette, IL.
For 25 years, the physicians at Metro Chicago Surgical Oncology have offered comprehensive gynecologic and urologic non-surgical, surgical, and radiation oncology treatments to cancer patients. The opening of MCSO Radiation Oncology Center immediately enhances MCSO’s current services by utilizing more advanced technologies.
Spearheaded by Timothy Hollister, M.D., a board certified radiation oncologist and active member of the American Society for Radiation Oncology (ASTRO), the MSCO Radiation Oncology Center gives patients access to exceptional physicians and today’s most advanced and clinically proven radiotherapy technologies. The center boasts innovative technologies including Cone Beam Computerized Tomography (CBCT), Intensity Modulated and Image-Guided Radiation Therapies (IMRT/IGRT), Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT).
“With the help of Vantage Oncology, we are able to provide advanced radiation oncology services to our patients in a state-of-the-art cancer care facility,” said Dr. Hollister. “Furthermore, this facility will enhance and ensure our served communities’ convenient access to the most precise and sophisticated cancer treatments available.”
IMRT and IGRT are two of the most significant innovations in radiation therapy technology used to treat cancer. By combining daily imaging to confirm the size and location of the tumor before each treatment session, radiation oncologists are able to more precisely treat tumors throughout the body. As a result, the patient’s normal healthy tissue is exposed to less radiation, thereby facilitating the preservation of healthy tissue and minimizing potential side effects and complications.
“Radiation therapy technologies such as IMRT and IGRT help physicians deliver higher doses of radiation to tumors with fewer complications and less immediate and long-term side effects,” explained Dr. Hollister. “With a coordinated multidisciplinary approach to radiation therapy now available under one roof, patients will have the best chance for achieving optimal treatment results with the added convenience of a local center.”
Dr. Hollister completed his residency in radiation oncology at Memorial Sloan-Kettering Cancer Center in New York and received his medical degree from the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin. He specializes in the treatment of prostate cancer, breast cancer, lung cancer, colorectal cancer, and head and neck cancer. As a cancer researcher, Dr. Hollister has presented his findings at national meetings and published studies in numerous medical journals. He is a research grant recipient and holds a U.S. Patent on an anti-cancer drug.
“I am extremely excited to be a part of the MCSO Radiation Oncology Center and believe it will rapidly become the gold standard for the planning and delivery of radiation oncology services in the Chicago North Shore area,” said Dr. Hollister.
For more information about MCSO Radiation Oncology Center or to schedule an appointment, please call (847) 512-1849 or visit us at
About Vantage Oncology
Founded in October 2002, Manhattan Beach, California-based Vantage Oncology, LLC, develops and operates radiation oncology centers of excellence through acquisitions and joint ventures. The company’s founding principal was to address the growing need among cancer patients, hospitals and physicians for easily accessible and advanced radiation treatment therapies. Vantage Oncology currently operates 46 treatment facilities in 13 states. Vantage Oncology is led by a seasoned management team including Chief Executive Officer and Co-Founder Michael Fiore, Chief Medical Officer and Co-Founder, Leslie Botnick, M.D., Chief Financial Officer Marshal Salomon and Chief Development Officer Mark Ahern. For more information about Vantage Oncology, visit www.vantageoncology.com.
About Metro Chicago Surgical Oncology
Metro Chicago Surgical Oncology (MCSO) is a multidisciplinary group dedicated to the diagnosis and treatment of cancer. For 25 years, the physicians at MCSO have offered comprehensive gynecologic and urologic non-surgical, surgical, and radiation oncology treatments to patients in an environment of wellness and compassionate care. For more information about MSCO, please call (847) 512-1849.
Tel: (949) 364-2821